Listing 1 - 10 of 52 | << page >> |
Sort by
|
Choose an application
Data integrity is a global mandatory requirement for the regulated healthcare industry. It is more than a mere expectation-it's a basic element of good documentation practices, one of the most fundamental pillars of a quality management system. Robustness and accuracy of the data submitted by manufacturers to regulatory authorities when bringing a medical product to market are crucial. The purpose of this book is to consolidate existing data integrity principles and expectations from several regulatory sources-including the U.S. Food and Drug Administration, World Health Organization, and European Medicines Agency-into a single and handy document that provides detailed, illustrative implementation guidance. It serves as a means of understanding regulatory agencies' position on good data management and the minimum expectation for how medical product manufacturers can achieve compliance.
Choose an application
Medical --- Pharmacy --- Pharmacy. --- Law and legislation. --- Pharmaceutical industry --- Pharmaceutical policy --- Narcotic laws --- Laws and legislation --- Law and legislation
Choose an application
Science --- Methodology --- AA / International- internationaal --- 303.0 --- Philosophy. --- Science. --- -#SBIB:303H510 --- Natural science --- Science of science --- Sciences --- Philosophical Overview --- Hedonism --- Stoicism --- Overview, Philosophical --- Overviews, Philosophical --- Philosophical Overviews --- Philosophies --- Statistische technieken in econometrie. Wiskundige statistiek (algemene werken en handboeken). --- Methoden sociale wetenschappen: statistische technieken, algemeen --- Methodology. --- Philosophy --- #SBIB:303H510 --- Pharmacy Philosophy --- Pharmacy Philosophies --- Philosophies, Pharmacy --- Philosophy, Pharmacy --- Scientific method --- Logic, Symbolic and mathematical --- Statistische technieken in econometrie. Wiskundige statistiek (algemene werken en handboeken) --- Science - Methodology --- History of science --- Probability theory --- Statistical theories
Choose an application
This book applies an established analytical framework for health sector reform (Getting Health Reform Right, Oxford, 2004) to the performance problems of the pharmaceutical sector. The book is divided into three sections. The first section presents the basic ideas for analysis. It begins by insisting that reform start with a clear understanding of the performance deficiencies of the current system. Like all priority setting in the public sector, this 'definition of the problem' involves both ethical choices and political processes. Early chapters explain the foundations of these ideas and appl
Pharmaceutical policy. --- Pharmaceutical industry. --- Health care reform. --- Health reform --- Health system reform --- Healthcare reform --- Medical care reform --- Reform of health care delivery --- Reform of medical care delivery --- Drug industry --- Drug trade --- Drug policy --- Drugs --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Government policy --- Medical policy --- Health insurance --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Chemical industry
Choose an application
Every four minutes, over 50 children under the age of five die. In the same four minutes, 2 mothers lose their lives in childbirth. Every year, malaria kills nearly 1.2 million people, despite the fact that it can be prevented with a mosquito net and treated for less than 1.50.Sadly, this list goes on and on. Millions are dying from diseases that we can easily and inexpensively prevent, diagnose, and treat. Why? Because even though we know exactly what people need, we just can't get it to them. They are dying not because we can't solve a medical problem but because we can't solve a logistics
Pharmaceutical policy --- Drugs --- Medical care --- World health. --- Global health --- International health --- Public health --- Medical geography --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Drug policy --- Drugs and state --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- International cooperation --- Government policy --- World health --- E-books
Choose an application
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr
Medicare --- Pharmaceutical services insurance --- Medical care, Cost of --- Health insurance --- Older people --- Medicaid --- Medigap --- Medical care --- E-books --- Medicare. --- Pharmaceutical policy. --- Drug policy --- Drugs --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- Drug benefit plans --- Drug insurance --- Insurance, Pharmaceutical services --- Pharmaceutical insurance --- Prepaid prescription drug plans --- Prescription drug insurance --- Prescription drug programs --- Insurance --- Government policy
Choose an application
Pharmaceuticals are an essential component of health care. But for many people in low- and middle-income countries, access to the medicines they need to prevent or treat severe illnesses is limited. Typical problems are lack of availability, costs that exceed the individual's purchasing power or lack of competent "agents" - health workers that are well trained to give the correct advice on which medicines to take. Pharmaceutical policy is the part of health policy that aims at addressing these problems and increasing access to safe, effective and affordable medicines for all patients. There ar
Pharmaceutical policy. --- Drug Industry --- Developed Countries. --- Government Regulation. --- Health Plan Implementation. --- Health Policy --- organization & administration. --- economics. --- Medical policy. --- Health care policy --- Health policy --- Medical care --- Medicine and state --- Policy, Medical --- Public health --- Public health policy --- State and medicine --- Science and state --- Social policy --- Drug policy --- Drugs --- Drugs and state --- Pharmacy --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- Government policy --- Health Plan Implementation --- organization & administration --- economics --- Developed Countries --- Government Regulation
Choose an application
In developing countries, 6 out of 10 people die from infectious diseases. Nearly 1 billion humans suffer from a neglected infectious disease, according to the World Health Organisation. Yet less than 1% of the new drugs placed on the market from 1975 to the turn of the century were developed for these diseases. This book looks at ways of improving the availability of medicines for infectious diseases through strengthened coherence in health, trade, science and technology, development co-operation and finance.
Hygiene. Public health. Protection --- Developing countries --- Pharmaceutical policy --- Pharmaceutical industry. --- Communicable diseases --- Médicaments --- Industrie pharmaceutique --- Maladies infectieuses --- Prevention --- Politique gouvernementale --- Prévention --- Drug development --- Pharmaceutical industry --- Contagion and contagious diseases --- Contagious diseases --- Infectious diseases --- Microbial diseases in human beings --- Zymotic diseases --- Diseases --- Infection --- Epidemics --- Development of drugs --- Drugs --- New drug development --- Pharmacology --- Pharmacy --- Drug policy --- Drugs and state --- Pharmacy and state --- State and drugs --- State and pharmacy --- Medical policy --- Development --- Government policy
Choose an application
Pharmacogenetics helps us understand the relationship between an individual’s genetic make-up and the way medicines work for each person. This book reviews the use of pharmacogenetics across all stages of the health innovation cycle from research through to uptake by doctors and patients. It focuses on how to optimise the use of pharmacogenetics to deliver effective innovations for public health, and design policies that enhance their economic and social benefits. The book argues for large-scale studies to validate the biomarkers that underpin pharmacogenetics and policies to share the cost and risk of using pharmacogenetics to improve the use of existing medicines. Governments and others need to align regulatory, reimbursement and other incentives and work with industry to measure better the impacts of pharmacogenetics. Health systems need to take positive steps to adapt to the use of pharmacogenetics and ensure that health professionals receive adequate training.
Behavior genetics. --- Pharmaceutical industry --Technological innovations. --- Pharmacogenetics. --- Pharmacogenetics --- Pharmaceutical industry --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Technological innovations --- Technological innovations. --- Pharmacology --- Genetic aspects --- Biochemical genetics --- Medical innovations
Choose an application
Drugs --- Pharmaceutical industry --- Pharmaceutical services --- Medical care --- Pharmacy --- Drug industry --- Drug trade --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Chemical industry --- Marketing. --- E-books
Listing 1 - 10 of 52 | << page >> |
Sort by
|